Across its top 1 institutional holders, ITCIEUR's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 5/100, avg. turnover score 20/100).
Quarterly Activity
Recent Activity
+$0.0
Total Buy Value
$0.0
Total Sell Value
New buy0
Trim0
Add0
Sold out0
0
Net Buyers
0
Net Sellers
Smart Money Convergence
ITCIEUR does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.
13F data as of 2026-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.
Insider Trading (Form 4)
Form 144 Pre-Sale Notices
No Form 144 planned sale filings in the last 90 days
Beneficial Ownership (13D/13G)
No Schedule 13D/13G filings for this ticker
Material Events (8-K)
No Form 8-K filings for this ticker
CUSIP
46116X101
FAQ
Who are the top institutional investors holding INTRA-CELLULAR THERAPIES INC (ITCIEUR)?
Major stakeholders currently include Huntington National Bank ($2.5K). Based on the latest 13F filings, there are a total of 1 tracked investment funds and institutions maintaining positions in ITCIEUR.
What is the overall institutional sentiment toward ITCIEUR recently?
Institutional sentiment appears Neutral. During the most recent reporting quarter, the stock experienced no significant net capital flow from tracked managers.
Which institutions have been selling or reducing their ITCIEUR positions?
In the latest period, no tracked funds trimmed or exited their positions in ITCIEUR.
Are there any notable investors adding ITCIEUR to their portfolios?
No tracked institutions opened new positions or added to their existing holdings in ITCIEUR during the last reporting period.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter